Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Aprea Therapeutics Inc (APRE)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Aprea Thera's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
5.930 +0.220    +3.85%
31/12 - Closed. Currency in USD ( Disclaimer )
After Hours
5.640
-0.290
-4.890%
17:20:27 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 8,448
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 5.710 - 6.007
Aprea Thera 5.930 +0.220 +3.85%

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

APRE Comments

Write your thoughts about Aprea Therapeutics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mongotroll Troll Troll
Mongotroll Feb 16, 2023 10:51AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what happened here?
Reply
0 0
Report
tal tal
tal tal Sep 13, 2022 12:47PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
??
Reply
0 0
Report
Xpeng Trader
Xpeng Trader May 17, 2022 10:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
this could be the end!
Reply
1 0
Report
Billy Bow
Billy Bow Mar 19, 2022 9:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
w
Reply
0 0
Report
Paco Bv
Pacob Sep 20, 2021 4:51PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
'The emerging data for the combination of eprenetapopt and pembrolizumab in these difficult-to-treat patients is very encouraging,” said Dr. Haeseong Park of Washington University in St. Louis. “Particularly promising are tumor reductions in lung cancer patients who previously received I/O therapy, and the complete remission in a bladder cancer patient with prior chemotherapy exposure, which is rare. In addition, the clinical experience to-date suggests the combination is well-tolerated with adverse events readily managed with standard of care measures. The other investigators and I look forward to maturation of the data from this clinical trial as we seek to enroll and treat additional patients with this novel combination.'
Reply
2 0
Report
Mongotroll Troll Troll
Mongotroll Sep 20, 2021 4:51PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Thanks, do you have any other interesting stock to buy ? look at the premarket.. hope it keeps like this tomorrow opening session
Reply
0 0
Report
Paco Bv
Pacob Sep 20, 2021 4:51PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Kinross Gold Corp (KGC) , gold is extremely cheap in a must-have resource at all levels: geopolitical, industrial, coin backing, etc, etc
Reply
0 0
Report
Mongotroll Troll Troll
Mongotroll Sep 20, 2021 4:51PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
only +5% in premarket...
Reply
0 0
Report
Paco Bv
Pacob Sep 20, 2021 12:37PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://ir.aprea.com/static-files/47be1f37-ac5f-4302-8ce1-7ad5d2c88839
Reply
0 0
Report
Paco Bv
Pacob Sep 20, 2021 12:33PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
It was today ~~ Date and Time: Monday, September 20, 2021; 17:35 – 17:40 CEST (11:35 – 11:40am EDT). At this moment APREA have not yet issued the content of the report, but already been. It must be a good report because not fallen too much
Reply
0 0
Report
Paco Bv
Pacob Sep 20, 2021 12:33PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I got it: Conclusions • Combination of eprenetapopt + pembrolizumab was safe and well-tolerated as evidenced by • Absence DLTs in the safety cohort • All grade AEs which were manageable with standard of care measures • 1 patient discontinued eprenetapopt due to AEs • Preliminary efficacy signal of disease reduction in 2 of 20 patients with NCSLC previously treated with IO therapy and 1/3 patients with IO-naïve bladder/urothelial cancer who achieved CR • Exploratory studies involving analyses of myeloid cells for inflammatory markers and immunosuppressive phenotype, and T cell phenotyping for exhaustion markers, are ongoing • The trial continues to enroll and treat patients
Reply
0 0
Report
Mongotroll Troll Troll
Mongotroll Sep 20, 2021 11:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ok I got 300 shares of this... bought at 4.98 based on a random comment from below. Trusting internet people... that's risky gambling
Reply
0 0
Report
Show previous replies (7)
Mongotroll Troll Troll
Mongotroll Sep 20, 2021 11:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Ok so there was no 100% raise, thanks for the fake info!
Reply
0 0
Report
Mongotroll Troll Troll
Mongotroll Sep 20, 2021 11:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Ok so there was no 100% raise, thanks for the fake info!
Reply
0 0
Report
Paco Bv
Pacob Sep 20, 2021 11:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
maybe the +100% on a good day, today was terrible, but if u BUY 4,98 and sold about 5,5X it's a good profit in a very red day
Reply
0 0
Report
Mongotroll Troll Troll
Mongotroll Sep 20, 2021 11:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
no way look the premarket now... will it hold until tomorrow ?
Reply
0 0
Report
Paco Bv
Pacob Sep 20, 2021 11:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
who knows! what a joke! pre today was at sometime like +20% rude manipulation
Reply
0 0
Report
Xpeng Trader
Xpeng Trader Sep 17, 2021 7:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why is it up 20% after market?
Reply
0 0
Report
Show previous replies (1)
Xpeng Trader
Xpeng Trader Sep 17, 2021 7:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I will be happy with $6
Reply
0 0
Report
Paco Bv
Pacob Sep 17, 2021 7:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I need something about $8, but $7,99 will work as well
Reply
0 0
Report
Mongotroll Troll Troll
Mongotroll Sep 17, 2021 7:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
not even in their website they announce any event
Reply
0 0
Report
Mongotroll Troll Troll
Mongotroll Sep 17, 2021 7:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ok you know what ? I bought some shares... let's see tomorrow if you were right. this is crazy, trusting somebody on the internet, lol
Reply
0 0
Report
Paco Bv
Pacob Sep 17, 2021 7:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
sorry, just copy and paste the text I wrote in the night yesterday, so it's today, see the SEC filling
Reply
0 0
Report
Paco Bv
Pacob Sep 14, 2021 8:10AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2021 from September 16 – 21, 2021.
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close

Make Smart Decisions.
Research, evaluate, and invest with unique market insights

Volatile markets create opportunities.
Don’t miss out.

Investing Insights
Investing Insights
Investing Insights

Read More

Invest with knowledge

Leverage the wisdom of financial experts and seize market opportunities.

  • Generate investment ideas based on leading Wall Street analyst recommendations.

  • Research trending stocks using 6 unique market factors.

  • Receive market updates in our Insights Newsletter.

Why Investing Insights

5 ways to boost your research

  • Objective stock score based on 6 market factors

  • Wall Street analyst price targets and ratings

  • Stock sentiment by bloggers, insiders, and financial gurus

  • News sentiment and score for thousands of stocks

  • Simplified screener with 3 ways to research investment ideas

  • Objective stock score based on 6 market factors

  • Wall Street analyst price targets and ratings

  • Stock sentiment by bloggers, insiders, and financial gurus

  • News sentiment and score for thousands of stocks

  • Simplified screener with 3 ways to research investment ideas

  • Objective stock score based on 6 market factors

  • Wall Street analyst price targets and ratings

  • Stock sentiment by bloggers, insiders, and financial gurus

  • News sentiment and score for thousands of stocks

  • Simplified screener with 3 ways to research investment ideas

Stay Ahead. Learn From the Pros.

For the stocks you research, we’ll bring you insights from

  • 6,500 Wall Street analysts

  • 40,000 corporate insiders

  • 7,000 financial bloggers

  • 200 leading hedge funds

  • 100,000 news stories daily

  • 100s of investment ideas

* For the U.S. stock market. We are continually expanding coverage.

Questions & Answers

  • What is Investing Insights?

    Investing Insights is a premium service that provides you with actionable insights from thousands of financial experts that cover the US stock market. Find out which stocks Wall Street analysts, insiders, financial bloggers, hedge fund managers and individual investors are recommending. Investing Insights is available only on our website. Canadian and UK stock markets will soon be added.

  • What is "Smart Score"?

    Smart Score is a powerful scoring system that ranks stocks on a scale of 1-10 based on 6 unique market factors. Smart Score is updated every evening after the market closes, 5 days a week.

  • Can I try Investing Insights for free?

    Yes. You can try Investing Insights for 14 days free of charge.
    The trial period will be followed by a paid subscription. To avoid being charged simply contact our support to cancel the subscription before the trial period ends.
    Please notice that purchases made through PayPal might be subjected to a temporary authorization.

  • How do I cancel my Investing Insights premium subscription?

    In order to cancel your subscription, please contact our support with your registered email or reference number and one of our agents will be happy to assist you.

  • Will I get notified before my subscription renewal?

    Our subscription has automatic renewal, meaning that when you reach the subscription end date, you will be charged automatically and your subscription will be extended. You can cancel your subscription anytime by following the instructions in the answer to the "How do I cancel my Investing Insights subscription" question. The subscription will remain active for the duration of the paid period.

  • What are the available payment methods?

    We accept all major credit cards and debit cards, including Visa, Mastercard, American Express, Discover, JCB, and Diners. Additional payment options may be available in your specific location

Got more questions?

We hope you found the answers you were looking for. You can read more about Insights here. Please go to the Investing Help Center for further information.

By subscribing you agree to TipRanks' Terms and Conditions and Privacy Policy

Powered by
Continue with Google
or
Sign up with Email